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Treatment of type 2 diabetes includes lifestyle and pharmacologic interventions. Drugs are 
marginally effective in achieving glycemic targets and reducing cardiovascular (CV) events, 
whereas intervention on lipids, blood pressure and lifestyle is more effective. Rethink Oraganization 
to iMprove Education And Outcomes (ROMEO) (ISRCTN19509463), a 4-year multicentre 
randomized trial, showed that patients with type 2 diabetes on Group Care (GC), a previously 
described systemic self-management education model, improved body weight, HbA1c, HDL and 
LDL cholesterol, blood pressure, quality of life and health behaviours, compared with patients on 
usual care and similar pharmacological treatment (1). The ROMEO dataset was fed into three risk 
engines: Framingham (2), UKPDS (3) and CUORE (4) to verify if GC modifies CV risk scores. 
 
A total 815 non insulin-treated patients aged <80 were allocated to either GC or traditional care 
(Controls). Risk calculations were performed at baseline and throughout the 4 years of the trial in 
466 patients (257 on GC and 209 Controls) who completed ROMEO. Reasons for dropping out 
were reported (5), and dropouts (105 GC and 128 controls) did not differ from other patients for any 
variables at baseline.  
 
A generalized least - square regression model was used to ascertain interactions between groups and 
time. A correlation structure was specified to account for repeated measures. A compound 
symmetry structure corresponding to a constant correlation resulted in the best fit model, based on 
Akaike Information Criterion (AIC). Model fitting was considered as significantly improved on the 
basis of the AIC applied backwards starting from a model with all relevant variables. The non-linear 
effect of covariates was modelled using a restrictive cubic-spline function. Interaction among 
variables was checked. To ensure normality assumptions, risk scores were modeled on a 
logarithmic scale. Data were analyzed with R. p<0.05 was considered significant. 
 
Four year trends are shown in Figure 1 for each risk model. Interactions between time and group 
showed that, using Framingham and CUORE, the risk for GC patients was 7.2% lower than in 
controls over 1 year (model coefficient: -0.006/month, p<0.0001). Using UKPDS, GC patients 
achieved a risk reduction of 3.6% over 1 year (p<0.0001).  
 
All three models showed lower CV risk among patients on GC compared to controls, despite 
similar pharmacological prescriptions. The Framingham and CUORE models are based upon North-
American and Italian cohorts and include diabetes as a dichotomous variable. The UKPDS score, 
developed in British patients with newly diagnosed type 2 diabetes, incorporates HbA1c and time 
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since diagnosis in a diabetes-specific model and was recently shown to accurately predict CV 
events also in Italian populations (3). Look AHEAD (Action for Health in Diabetes), an 
independent clinical trial, reported that lifestyle intervention does not reduce CV events in type 2 
diabetes (5). However, since it compared an intensive lifestyle intervention with a less intensive 
group education approach, it could be argued that Look AHEAD did not disprove the effectiveness 
of lifestyle modification, but rather proved the non inferiority of a highly intensive intervention over 
a more sustainable pragmatic approach, similar in part to our GC model at least in timing if not 
education philosophy and methodology. 
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Figure 1. Temporal trends of cardiovascular risk measured by Framingham, UKPDS and CUORE 
Risk Scores, estimated using locally weighted regression.  
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